TD Cowen has reaffirmed a positive stance on Axsome Therapeutics, naming the company among its "Best Smidcap Ideas 2026" and raising its 12-month price target to $300 from $275. The brokerage kept a "buy" rating on the stock, underlining both current commercial momentum and future pipeline potential as the basis for its conviction.
The firm highlighted the launch of Auvelity for agitation associated with Alzheimer’s disease as gaining traction, while also noting ongoing growth for the drug in major depressive disorder. TD Cowen said physician survey data point to a sizable addressable market for Auvelity, and argued that this commercial opportunity is not fully reflected in the stock price.
Beyond Auvelity, TD Cowen pointed to multiple late-stage pipeline candidates addressing a range of central nervous system indications. The brokerage specifically listed narcolepsy, attention-deficit/hyperactivity disorder, binge eating disorder, shift work disorder and other CNS indications as areas where Axsome has assets in late development. TD Cowen said these programs are underappreciated by the market and therefore create additional upside potential for the company.
The upgraded price target to $300 implies further appreciation from Axsome Therapeutics' June 16 closing price of $251.91, according to the brokerage. The firm framed its view around a combination of an accelerating commercial launch and a late-stage pipeline that, in its assessment, has yet to be fully incorporated into Axsome's valuation.
Context and implications
TD Cowen's update blends commercial execution considerations with pipeline valuation. The brokerage's argument rests on two pillars: first, market uptake and physician interest for Auvelity in Alzheimer’s agitation and major depressive disorder; second, a set of late-stage CNS programs that the firm believes are not priced into the stock. Together, these factors form the rationale for maintaining a buy rating and increasing the price target.
What the market is expected to watch
- Commercial uptake data and physician feedback on Auvelity as its launch progresses.
- Clinical and regulatory developments for Axsome's late-stage CNS pipeline programs.
- Share-price reaction to the revised $300 target relative to the June 16 close of $251.91.